COMMUNIQUÉS West-GlobeNewswire

Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
19/03/2025
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
19/03/2025
The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class [...]
Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas
19/03/2025
New Plasma Collection Center in San Antonio has Planned Annual Collection Capacity of Approximately 50,000 Liters Center Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D Specialty [...]
Auron Therapeutics Expands Leadership with Appointment of Glenn Goddard as Chief Financial Officer
19/03/2025
NEWTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics , a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today [...]
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
19/03/2025
-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months [...]
Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements
19/03/2025
$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in immuno-inflammation and immuno-oncology planned to enter IND-enabling [...]
XORTX Announces Update for Discussion with the FDA
19/03/2025
● Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU [...]
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
19/03/2025
Dr. Baumgartner will advance Applied’s preparation for upcoming regulatory interactions NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to [...]
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
19/03/2025
65% oncology products revenue growth drove profitable operation and supported new ATTC platform HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”, [...]
MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
19/03/2025
Initiated VALUE, a global Phase III pivotal trial of EscharEx ® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million [...]
ANI Pharmaceuticals Announces the Launch of Nitazoxanide Tablets
19/03/2025
PRINCETON, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic [...]
VIVUS’ QSYMIA® to be Featured on Health Uncensored with Dr. Drew
19/03/2025
— Segment to air on Lifetime on Wednesday, March 19, at 7:30 AM ET/PT CAMPBELL, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of [...]
Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership
19/03/2025
Allogenica Secures €2.5 Million Grant to Advance Universal CAR-T Therapy and Strengthen France’s Biotherapy Leadership Allogenica received a €2.5 million grant from the French government 's France 2030 program to [...]
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
19/03/2025
Collaboration leverages OBT’s proprietary OGAP®-Verify discovery platform and Roche’s drug development expertise to advance multiple selected novel oncology targets OBT to receive up to US$36 million upfront payments [...]
ONWARD Medical Schedules Reporting of Full Year 2024 Financial Results and Business Update Webcast
19/03/2025
EINDHOVEN, the Netherlands, March 19, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, [...]
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
19/03/2025
Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also [...]
Nicoxannonce que la visite finale du dernier patient a été effectuée dans l’étude de phase 3b Whistler sur le NCX 470 pour le glaucome
19/03/2025
Communiqué de presse Nicox annonce que la visite finale du dernier patient a été effectuée dans l’étude de phase 3b Whistler sur le NCX 470 pour le glaucome Résultats de l'étude attendus en mai 2025 Visite finale du [...]
Ipsen announces issuance of €500 million inaugural Rated Public Bond
19/03/2025
Transaction follows Investment Grade ratings assignment from both S&P and Moody’s PARIS, FRANCE, 19 March 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today announced [...]
Ipsen annonce le succès de son émission obligataire inaugurale notée d'un montant de 500 millions d'euros
19/03/2025
Cette transaction fait suite à l’attribution, par S&P et Moody’s, de notations de crédit ‘Investment Grade’ PARIS, FRANCE, 19 mars 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de [...]

Pages